Table 5.

Results of phase III clinical trials of idiotype vaccines in follicular lymphoma

Study	No. of patients, target disease	Regimen of induction therapy	Eligibility	Vaccine type	Vaccine production methodology	Primary end point
	No. of patients, target disease	Regimen of induction therapy			Vaccine production methodology	Survival types, P-value, significance
Biovest	n = 177, untreated FL	PACE or R-CHOP	CR	Id-KLH/GM-CSF	Rescue hybridoma	Disease-free survival, P > 0.05, not significant
Genitope	n = 287, untreated FL	CVP	CR, PR	Id-KLH/GM-CSF	Recombinant DNA	Progression-free survival, P > 0.05, not significant
Favrille	n = 349, untreated or recurrent FL	Rituximab	CR, PR, SD	Id-KLH/GM-CSF	Recombinant DNA	Time to progression, P > 0.05, not significant

FL: Follicular lymphoma; PACE: Prednisolone, doxorubicin, cyclophosphamide and etoposide; R-CHOP: Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisolone; CVP: Cyclophosphamide, vincristine, prednisolone; CR: Complete response; PR: Partial response; SD: Stable disease; Id-KLH: Idiotype-keyhole limpet hemocyanin; GM-CSF: Granulocyte-macrophage colony stimulating factor.